Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies by Nathaly Enciso, José Amiel, Fredy Fabián-Domínguez, Jhon Pando, Nancy Rojas, Carlos Cisneros-Huamaní, Ernesto Nava, Javier Enciso

“…Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. …”
Get full text

Curcumin-loaded nanostructured lipid carrier induced apoptosis in human HepG2 cells through activation of the DR5/caspase-mediated extrinsic apoptosis pathway by Wang Fengling, Ye Xi, Zhai Dandan, Dai Wenting, Wu Yifan, Chen Jin, Chen Weidong

“…Therefore, Cur-NLC induced activation of the extrinsic apoptosis pathway via modulating the DR5/caspase-8/-3 mediated apoptosis pathway in HepG2 cells, suggesting that Cur-NLC is a promising therapeutic agent or supplement for the treatment of hepatocellular carcinoma.…”
Get full text

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary by Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

“…Model states were fibrosis (F0–F4, defined using METAVIR fibrosis scores), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), and liver-related deaths (LD). …”
Get full text

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus by A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya

“…NAFLD is associated with an increased cardiovascular risk (due to association with “metabolic syndrome”) and the risks of liver cirrhosis and hepatocellular carcinoma. Macro- and microvascular complications in T2D comorbidity entail a higher overall mortality. …”
Get full text

Hepatitis C Worldwide and in Brazil: Silent Epidemic—Data on Disease including Incidence, Transmission, Prevention, and Treatment by Iara Fabricia Kretzer, Andrea do Livramento, Joel da Cunha, Sabrina Gonçalves, Iraci Tosin, Celso Spada, Aricio Treitinger

“…The infection is a leading cause of liver diseases like cirrhosis and hepatocellular carcinoma (HCC); thus, HCV infection constitutes a critical public health problem. …”
Get full text

An untargeted metabolomic analysis of acute AFB1 treatment in liver, breast, and lung cells. by Heidi H Cao, Sabrina Molina, Susan Sumner, Blake R Rushing

“…Aflatoxin B1 (AFB1) is a class 1 carcinogen and mycotoxin known to contribute to the development of hepatocellular carcinoma (HCC), growth impairment, altered immune system modulation, and malnutrition. …”
Get full text

Liver Transplantation for Alcohol-Related Liver Disease (ARLD): An Update on Controversies and Considerations by Dipesh Kumar Yadav, Qi Zhang, Xueli Bai, Enliang Li, Tingbo Liang

“…According to the recent data from the United Network for Organ Sharing database, alcohol-related liver disease (ARLD) accounts to be the most common indication of liver transplantation (LT) waiting lists in the United States among men without hepatocellular carcinoma (HCC). Severe alcoholic hepatitis (AH) is serious and the life-threatening form of ARLD and should be treated timely. …”
Get full text

INTERNATIONAL NORMALIZED RATIO AND ACTIVATED PARTIAL THROMBOPLASTIN TIME DO NOT PREDICT PLASMA TRANSFUSION IN LIVER TRANSPLANTATION by David Silveira MARINHO, Joel Avancini ROCHA FILHO, Estela Regina Ramos FIGUEIRA, Claudia Regina FERNANDES, Rui Carlos DETSCH JUNIOR, José Huygens Parente GARCIA, Wellington ANDRAUS, Luiz Augusto Carneiro D’ALBUQUERQUE

“…RESULTS: Multivariate analysis showed that preoperative hematocrit (odds ratio [OR]=0.90, p<0.001), preoperative fibrinogen (OR=0.99, p<0.001), and absence of hepatocellular carcinoma (OR=3.57, p=0.004) were significant predictors of plasma transfusions. …”
Get full text

Antimicrobial and antiproliferative activity of biosynthesized manganese nanocomposite with amide derivative originated by endophytic Aspergillus terreus by Nashwa El-Gazzar, Reem Farouk, Nervana S. Diab, Gamal Rabie, Basel Sitohy

“…Furthermore, MnNCs were reduced hepatocellular carcinoma viability. Conclusion The use of HDOCOX, either alone or in combination with MnNPs, is a potential candidate for inhibiting pathogenic microbes and the development of an anticancer drug pipeline.…”
Get full text

Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020 by Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu

“…Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a primary cause of chronic liver disease, with potential progression to cirrhosis and hepatocellular carcinoma (HCC). Although systemic inflammatory biomarkers are associated with liver diseases, their specific role in MASLD remains unclear. …”
Get full text

Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer by Sushma Yadav, Claudia M. Kowolik, Daniel Schmolze, Yuan Yuan, Min Lin, Arthur D. Riggs, David A. Horne

“…However, recent studies have unveiled its pivotal role in epithelial–mesenchymal transition (EMT), metastasis, and chemo- and radio-resistance in cancer cells. In hepatocellular carcinoma, aberrant phosphorylation of SMC1A has been associated with enhanced cell proliferation and migration. …”
Get full text

Recovery from Liver Failure and Fibrosis in a Rat Portacaval Anastomosis Model after Neurointermediate Pituitary Lobectomy by Martín Muñoz-Ortega, Noé Macías-Segura, Javier Ventura-Juárez, Manuel Enrique Ávila-Blanco, Leonardo D. Ponce-Damian, Daniel González-Blas, Esperanza Sánchez-Alemán, Andrés Quintanar-Stephano

“…Liver diseases, including cirrhosis, viral hepatitis, and hepatocellular carcinoma, account for approximately two million annual deaths worldwide. …”
Get full text

Genotyping of HCV RNA Reveals That 3a Is the Most Prevalent Genotype in Mardan, Pakistan by Sajid Ali, Ayaz Ahmad, Raham Sher Khan, Sanaullah Khan, Muhammad Hamayun, Sumera Afzal Khan, Amjad Iqbal, Abid Ali Khan, Abdul Wadood, Taj Ur Rahman, Ali Hydar Baig

“…The clinical outcomes of patients infected with hepatitis C virus (HCV) range from acute resolving hepatitis to chronic liver diseases such as liver cirrhosis or hepatocellular carcinoma. Identification of the infecting virus genotype is indispensable for the exploration of many aspects of HCV infection, including epidemiology, pathogenesis, and response to antiviral therapy. 1419 individuals were screened for anti-HCV in this study, of which 166 (11.7%) were found reactive by ICT (Immunochromatographic test). …”
Get full text

Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society by V. T. Ivashkin, M. V. Mayevskaya, Ch. S. Pavlov, Yu. P. Sivolap, V. D. Lunkov, M. S. Zharkova, R. V. Maslennikov

“…The alcoholic liver disease (ALD) is a clinical and morphological entity that encompasses several forms of the liver parenchyma lesions resulting from alcohol abuse, that range from steatosis to alcoholic hepatitis (steatohepatitis) followed by progression to fibrosis, liver cirrhosis and hepatocellular carcinoma. Alcoholic liver cirrhosis gives significant impact to digestive disease associated motility. …”
Get full text

Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk by Luca Miele, Cristina Bosetti, Federica Turati, Gianlodovico Rapaccini, Antonio Gasbarrini, Carlo La Vecchia, Stefania Boccia, Antonio Grieco

“…Metabolic conditions, including type 2 diabetes, have been related to hepatocellular carcinoma (HCC) risk. We have further analyzed the role of diabetes and antidiabetic treatments on HCC. …”
Get full text

Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer by Qinyuan Gong, Qinyuan Gong, Rongzhen Xu, Rongzhen Xu

“…In contrast, K102-Env markedly increased in patients with PDAC, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC) compared with healthy controls. …”
Get full text

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease by Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S, Chen Z, Wang Q, Xu J, Tu Q, Chen H, Zhu L

“…Yun Mao,1,&ast; Huilan Chen,1,&ast; Weihan Zhu,2 Shunlan Ni,3 Shengnan Luo,3 Shiyue Tang,3 Zhiyi Chen,4 Qin Wang,3 Jinxian Xu,3 Qi Tu,5 Haijun Chen,3,&ast; Lujian Zhu3,&ast; 1Department of Gerontology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China; 2The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 3Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China; 4Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China; 5Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Lujian Zhu; Haijun Chen, Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People’s Republic of China, Email zhulj_brave@163.com; 19564367335@163.comAbstract: Chronic liver disease ranks as the 11th leading cause of death worldwide, while hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality, representing a substantial risk to public health. …”
Get full text

The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells by Sabrina Bimonte, Maddalena Leongito, Antonio Barbieri, Vitale del Vecchio, Michela Falco, Aldo Giudice, Raffaele Palaia, Vittorio Albino, Raimondo Di Giacomo, Antonella Petrillo, Vincenza Granata, Francesco Izzo

“…Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide malignancy and the third leading cause of cancer death in patients. …”
Get full text

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion by V. V. Tsukanov, M. F. Osipenko, E. V. Beloborodova, M. A. Livzan, I. B. Khlynov, S. A. Alekseenko, Yu. P. Sivolap, J. L. Tonkikh, A. V. Vasyutin

“…In the treatment of NAFLD, diet and lifestyle modification, weight loss, the use of insulin sensitizers, vitamin E, statins (in the presence of hyperlipidemia) and drugs with metabolic activity are effective.Currently, a point of view is being actively expressed about the synergism of the action of alcohol and the metabolic syndrome on the development of fibrosis, cirrhosis, and hepatocellular carcinoma. The current international consensus recommends a change in the nomenclature of NAFLD and ALD and proposes the terms “metabolically associated steatotic liver disease” and “metabolically associated alcoholic liver disease”.Conclusion. …”
Get full text

Pathological Diagnosis of Hepatocellular Cellular Adenoma according to the Clinical Context by Paulette Bioulac-Sage, Christine Sempoux, Laurent Possenti, Nora Frulio, Hervé Laumonier, Christophe Laurent, Laurence Chiche, Jean Frédéric Blanc, Jean Saric, Hervé Trillaud, Brigitte Le Bail, Charles Balabaud

“…When the whole nodule is a hepatocellular carcinoma, it is extremely difficult to prove that it is the consequence of a former HCA. …”
Get full text